Asset profile
AV-101
Small molecule
Evidence outlook · lead readout
ELEVATE (NCT03078322) · Major Depressive Disorder
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
ELEVATE (NCT03078322): The study was randomized and quadruple-blind, compared AV-101 with placebo, and enrolled 180 participants; its primary endpoint was the clinical MADRS-10 depression score. Because the registry does not report whether the primary endpoint was met, the trial provides promising design information but no confirmed evidence of benefit.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
127 competitors in this universe: 11 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication; 27 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AV-101: this drug | Phase 3 | Small molecule | NMDA receptor | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Esketamine (Spravato) | Approved | Small molecule | NMDA receptor | ||
| ACP-211 | Phase 2 | Small molecule | NMDA receptor | ||
| Arketamine (PRT042) | Phase 2 | Small molecule | NMDA receptor | ||
| BI 1569912 | Phase 2 | Small molecule | NMDA receptor | ||
| Blixeprodil | Phase 2 | Small molecule | NMDA receptor | ||
| CLE-100 | Phase 2 | Small molecule | NMDA receptor | ||
| Onfasprodil | Phase 2 | Small molecule | NMDA receptor | ||
| Zelquistinel | Phase 2 | Small molecule | NMDA receptor | ||
| ALA-3000 | Phase 1 | Small molecule | NMDA receptor | ||
| SP-101 | Phase 1 | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) |
…and 112 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.